Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABFRA:DMN -3.97%41 Median PS Value is €0.28 as of Aug. 10, 2026, which is 100% below its 10-year median of 3.88. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review. Among 278 Biotechnology companies, Diamyd Medical AB ranks better than 82.73% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Diamyd Medical AB (FRA:DMN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Diamyd Medical AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.0725
/
0.28
=
0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB Median PS Value Related Terms
Diamyd Medical AB Median PS Value Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMN vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
Diamyd Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (FRA:DMN) has a Median PS Value of €0.28 as of Aug. 10, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Diamyd Medical AB and its competitors. This is 93% below median its historical median of 3.88. Over the past decade, Diamyd Medical AB's Median PS Value has ranged from 0.26 to 20.18. According to the industry distribution chart, Diamyd Medical AB ranks #48 out of 278 companies in the Biotechnology industry, placing it in the top 17.3%.
Is Diamyd Medical AB's Median PS Value too high?
Diamyd Medical AB's current Median PS Value of €0.28 is 93% below median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 20.18. Based on the distribution chart, Diamyd Medical AB ranks #48 out of 278 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #48 out of 278 companies for Median PS Value. This places Diamyd Medical AB in the top 17% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.63. Historically, Diamyd Medical AB's own Median PS Value has ranged from 0.26 to 20.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Median PS Value is €0.28, which is 93% below median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current Median PS Value is €0.28, which is 93% below median its 10-year median of 3.88. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Median PS Value is €0.28 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued.
The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Diamyd Medical AB to be Fairly Valued.
Key valuation signals for FRA:DMN:
Median PS Value: €0.28 (93% below median its 10-year median of 3.88)
GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for FRA:DMN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMN has been successfully added to your 
